Bionano Genomics (BNGO.Q) is a disruption play. The company is a structural variation company focusing on the next generation of cytogenomics with optical genome mapping. For in…
Biotech
Adaptimmune Therapeutics (ADAP.Q) announced today that it has entered into a strategic collaboration and license agreement with Genentech, a member of the Roche Group, to develop and commercialize allogenic…
In this episode, we talk about DIAGNOS (ADK.V), a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging, and traditional data mining thereby improving decision…
Chris Parry speaks with Andre Larente, president and CEO of DIAGNOS (ADK.V) to get an in-depth look at how their diabetic retinopathy screening services work and what it means…
XPhyto Therapeutics (XPHY.C), with its partner and acquisition target, 3a-diagnostics GmbH announced today that it has successfully registered its first biosensor test in oral inflammation with the German authorities….
Medexus Pharmaceuticals (MDP.TO) is a rare disease pharmaceutical company with a portfolio of innovative and high value rare disease products positioning the company for growth in the next decade…
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine…
Awakn Life Sciences (AWKN.NE) announced it has received ethical approval to conduct the first-ever study of the effects of ketamine on gambling addiction. Awakn has begun to recruit patients…
Mindset Pharma (MSET.C) announced they have filed a new patent with the US Patent and Trade Office (USPTO), extending its Family 4 compounds, a set of novel DMT/5-MeO-DMT analogs….
PolarityTE (PTE.Q) has provided an update regarding correspondence from the U.S. Food and Drug Administration (FDA) related to the Company’s Investigational New Drug Application (IND) for SkinTE®, which was…